KH-903 is under clinical development by Chengdu Kanghong Pharmaceuticals Group and currently in Phase II for Metastatic Colorectal Cancer.

Lisocabtagene maraleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Unspecified B-Cell Lymphomas.

Calquence is under clinical development by AstraZeneca and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.

Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Mantle Cell Lymphoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Bemarituzumab is under clinical development by Amgen and currently in Phase III for Bladder Cancer. According to GlobalData, Phase III drugs for Bladder Cancer have a 47% phase transition success rate ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Teriparatide biosimilar is under clinical development by TSH Biopharm and currently in Phase I for Osteoporosis.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GNT-0003 is under development for the treatment of crigler-najjar syndrome. The drug candidate is administered through intravenous route. Direct administration of an AAV (adeno-associated virus) ...

Cladribine is under development for the treatment of neurological diseases including neuromyelitis optica and neuromyelitis optica spectrum disorder, myasthenia gravis (MG). It is administered through ...